References
- Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: A clinical trial. Ann Intern Med 1980; 93: 391–8
- Dudgeon D, Lertzman M, Askew G. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage 2001; 21(5)373–9
- British Columbia Ministry of Health and Ministry Responsible for Seniors. Guidelines and Medical Indications for Home Oxygen Therapy. February, 1998
- Heyse-Moore L, Beynon T, Ross V. Does spirometry predict dyspnea in advanced cancer?. Palliat Med. 2000; 14: 189–95
- Borg G AV. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377–81
- Mahler D A. The measurement of dyspnea during exercise in patients with lung disease. Chest May, 1992; 101(5 Suppl)242S–247S
- Oxford Centre for Evidence-Based Medicine 2001, URL: http:/www.cebm.net/levels_of_evidence.asp
- Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: The use N of 1 randomized controlled trial. J Pain Symptom Manage Aug, 1992; 7(6)365–8
- Bruera E, deStoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnea in hypoxaemic terminal-cancer patients. Lancet 1993; 342: 13–4
- Booth S, Kelly M, Cox N, Adams L, Guz A. Am J Respir Crit Care Med. 1996; 153: 1515–8
- Swinburn C, Mould H, Stone T, Corris P, Gibson G J. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis 1991; 143: 913–15
- Liss H P, Grant B JB. The effect of nasal flow on breathlessness in pts with COPD. Am Rev Respir Dis 1988; 137(6)1285–8
- Nekolaichuk C L, Maguire T O, Suarez-Almazor M, Rogers W T, Bruera E. Assessing the reliability of patient, nurse, and family caregiver symptom ratings in hospitalized advanced cancer patients. J Clin Oncol 1999; 17(11)3621–30
- Bruera E, Sweeney C, Willey J, Palmer J L, Strasser F, Morice R C, Pisters K. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003; 17: 659–63
- Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993; 119: 906–7
- Poole P J, Veale A G, Black P N. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1877–80, 6 Pt 1
- Allard P, Lamontagne C, Bernard P, Tremblay C. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage 1999; 17: 256–65
- Jennings A L, Davies A, Higgins J PT, Broadley K. Opioids for the palliation of breathlessness in terminal illness (Cochrane Review). The Cochrane Library. Update Software, Oxford 2001, Issue 4
- Booth S, Wade R. Oxygen or air for palliative of breathlessness in advanced cancer. J R Soc Med 2003; 96: 215–8
- Booth S, Anderson H, Swannick M, Wade R, Kite S, Johnson M. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the scientific committee of the association ofpalliative medicine. Resp Med 2004; 98: 66–77
- Patel A, Jaeschke R, Guyatt G H, Keller J L, Newhouse M T. Clinical Usefulness of n-of-1 randomized controlled trials in patients with nonreversible chronic airflow limitation. Am Rev Respir Dis 1991; 144(4)962–4
- Nikles C J, Glasziou P P, Del Mar C B, Duggan C M, Mitchell G. N of 1 trials. Practical tools for medication management. Aust Fam Physician 2000; 29(11)1108–12
- Abernethy A P, Currow D C, Frith P, Fazekas B S, McHugh A, Chuong B. Randomized, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327: 523–8